A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Active, not recruiting · Phase 3 · NCT05552976
Conditions: Relapsed or Refractory Multiple Myeloma
At a glance
- Research payments reported, 2025
- $9,542
- U.S. investigators named
- 4
- Sites paid
- 4
- Planned or actual enrollment
- 606
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Mezigdomide (drug), Carfilzomib (drug), Dexamethasone (drug)
- Dates
- Started 2023-01-10; completion 2029-07-25
- Results posted
- Not yet
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
From ClinicalTrials.gov, last updated 2026-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $9,542 in research payments for this study in 2025 (4 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ashraf R. Aziz, MD Hematology & Oncology · Anaheim, CA
- Iuliana Shapira, MD Hematology & Oncology · Little Silver, NJ
- James J. Ignatz-hoover, MD, PHD Hematology & Oncology · Cleveland, OH
- Tondre Buck, M.D. Hematology & Oncology · Spartanburg, SC
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gibbs Cancer Center & Research Institute $4,506
- Kaiser Permanente Alton Sand Canyon Medical Offices $2,785
- Uh Cleveland Medical Center, OH $1,396
- Regional Cancer Care Associates $854
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.